<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="373901">
  <stage>Registered</stage>
  <submitdate>31/10/2017</submitdate>
  <approvaldate>7/11/2017</approvaldate>
  <actrnumber>ACTRN12617001542381p</actrnumber>
  <trial_identification>
    <studytitle>A randomized, open-label study evaluating the effects of food and dosing regimen on Q-122 pharmacokinetics in healthy female volunteers
</studytitle>
    <scientifictitle>A randomized, open-label study evaluating the effects of food and dosing regimen on Q-122 pharmacokinetics in healthy female volunteers
</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Protocol Q122-1002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Vasomotor symptoms in breast cancer patients/survivors</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other endocrine disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Part 1:  single oral dose of 200mg Q-122 on Day 1 and on Day 11.
Subjects will receive one dose after a high fat meal, and the other after fasting at least 10 hours.

Part 2:  200mg Q-122 orally once daily for 10 days, or 100mg Q-122 orally twice daily for 10 days.
Subjects remain in the trial unit during the entire dosing period to ensure compliance.</interventions>
    <comparator>Part 1:  fed or fasted dosing
Part 2:  once or twice daily dosing</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Part 1:  Single dose plasma PK parameters including Cmax, Tmax, t1/2, Kel, AUC0-inf, AUClast, %AUCexp, Clast, Tlast, Cl/F, and Vd/F under fed and fasted conditions.</outcome>
      <timepoint>PK samples collected pre dose and at 0.25, 0.5, 1.0, 1.5, 2, 3, 4, 8, 10, 12, 16, 24, 36, 48, 60, 72, and 96 hours post dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Part 2:  Repeat dose PK parameters including Cmax, Ctrough, Tmax, t1/2, Kel, AUC0-inf, AUClast, AUCtau, Cavg. Cmin, %Fluctuation</outcome>
      <timepoint>PK samples collected pre dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 8, 10, 12 and 16 hrs post dose 1, pre dose on Days 2 to 10, and 24, 36, 48, 60, 72 and 96 hrs post dose 10.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Part 1 and Part 2:  Safety data including adverse events, physical examination findings, vital signs, ECGs and clinical laboratory results</outcome>
      <timepoint>Part 1:  From baseline to Day 18
Post baseline time points;
- Vitals signs pre and post dose, Days 4, 10, 14 and 18
- Physical exam Days 2, 4, 10, 12, 14 and 18
- ECG Days 10 and 18
- Lab tests Days 3, 5 10, 13, 15 and 18

Part 2:  From baseline to Day 17
Post baseline time points
- Vitals signs Day 1 pre and post dose, Days 10, 13, 14 and 17
- Physical exam Days 13 and 17
- ECG Day 17
- Lab tests Days 6, 10 and 17</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Female subjects 45 years of age or older.
- generally healthy absent any clinically significant and relevant abnormality
- of non-childbearing potential.
- willing to adhere to the visit and assessment schedule, and protocol restrictions</inclusivecriteria>
    <inclusiveminage>45</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>- Clinically relevant history of hepatic, renal, pulmonary, psychiatric, or infectious disorders that would interfere with study procedures
- History of stomach banding or other surgery, Crohns disease, ulcerative colitis, (diabetic) gastroparesis, irritable bowel syndrome, irregular bowel habit, GI stoma, colostomy
- Pregnant or nursing
- febrile illness within 7 days of the planned first dose of study drug.
- Participation in a clinical trial with an Investigational Product within 30 days prior to Day 1. 
- Current use of tobacco, or use within 3 months of screening.
- History of substance abuse or alcohol consumption exceeding 14 drinks/week.
- Clinical laboratory abnormalities:
 ALT or AST &gt; Grade 1
 Total Bilirubin &gt; Grade 1
 Serum Creatinine &gt; Grade 1
 Hematology values &gt; upper limit of normal
- Clinically significant ECG abnormalities
- Use of medications that increase gastric pH or affect gastric motility
- Body mass index &gt; 38.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>29/11/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <currentsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Que Oncology</primarysponsorname>
    <primarysponsoraddress>Level 9, 31 Queen Street
Melbourne, VIC 3000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Que Oncology</fundingname>
      <fundingaddress>Level 9, 31 Queen Street
Melbourne, VIC 3000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Q-122 is being developed by QUE Oncology as a treatment for vasomotor symptoms (hot flashes) in female breast cancer patients/survivors. Q-122 has been studied in three Phase 1 clinical trials in cancer patients, healthy volunteers, and breast cancer survivors taking anti-estrogen therapy who were experiencing VMS.  This study is designed to determine the effect of food on Q-122 pharmacokinetic (PK) parameters (Part 1) and PK parameters following a once daily or twice daily dosing regimen.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Submitted, not yet approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Bellberry Limited</ethicname>
      <ethicaddress>129 Glen Osmond Road
Eastwood
South Australia 5063Â </ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>4/10/2017</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Nicholas Farinola</name>
      <address>CMAX Clinical Research Pty Ltd
Level 5, 18a North Terrace
Adelaide SA 5000</address>
      <phone>+61 8 7088 7900 </phone>
      <fax />
      <email>nicholas.farinola@sa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Rob Crombie</name>
      <address>QUE Oncology Pty Limited
Level 9, 31 Queen Street
Melbourne, VIC 3000</address>
      <phone>+61 3 9657 0731</phone>
      <fax />
      <email>rcrombie@queoncology.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Rob Crombie</name>
      <address>QUE Oncology Pty Limited
Level 9, 31 Queen Street
Melbourne, VIC 3000</address>
      <phone>+61 3 9657 0731</phone>
      <fax />
      <email>rcrombie@queoncology.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>